According to incomplete statistics from Innovation Insights, last week (September 8 to September 14)Global Health Sector Discloses 30 Financing Events with a Total Amount Exceeding $9.6 Billion, financing for innovative drugs increased.

Last week, large amounts of capital were concentrated in the later-stage financing (post-Series B) phase, injecting strong momentum into innovative drug companies.

Odyssey Therapeutics Completes $213 Million Series D Financing, having raised nearly $700 million in cumulative financing over four years since its establishment. The funds will primarily advance clinical proof-of-concept studies for multiple projects in the fields of autoimmune diseases and inflammation, including its RIPK2 inhibitor, which is currently in Phase 2 trials for ulcerative colitis, covering both monotherapy and combination therapy with Takeda's Entyvio. Top-line data for the monotherapy is expected to be released in the first half of 2026. The financing will also be used to develop the preclinical pipeline.

LB Pharma Breaks Biotech IPO Deadlock, Lists on NASDAQ on September 11 Raising $285 MillionThe funds will primarily support the Phase 3 clinical trial of the core pipeline LB-102 for the treatment of schizophrenia, with topline data expected to be released in the second half of 2027. Additionally, a Phase 2 clinical trial for the drug's treatment of bipolar depression will be conducted, with data expected to be announced in Q1 2028.

Similarly focused on the CNS field,NRG Therapeutics Completes $67 Million Financing, will advance the clinical proof-of-concept for NRG5051 in treating Amyotrophic Lateral Sclerosis (ALS)/Motor Neuron Disease (MND), while also conducting a Phase 1b clinical study in Parkinson's disease patients. NRG5051 is a novel modulator of mPTP. Pathological proteins in Parkinson’s disease (α-synuclein) and ALS/MND (TDP-43) are toxic to mitochondria and lead to mitochondrial dysfunction. Preclinical model studies have shown that inhibiting mPTP can protect mitochondria from this acquired functional proteotoxicity and preserve neuronal survival.

Gene editing sector sees active financing, particularly outstanding in China.

For chronic diseases,Epigenic Therapeutics, Inc. Completes $60 Million Series B Financing, the company will mainly advance the clinical development of the epigenetic innovative drug EPI-003 for functional cure of chronic hepatitis B and EPI-001 for the treatment of hypercholesterolemia. The company's core technology platform, EPIREG, achieves target gene silencing through DNA methylation and histone modification, offering a safer treatment option for chronic diseases. In addition, its LNP delivery platform can precisely deliver to the liver and extrahepatic organs, expanding the therapeutic scope; the AIAID platform empowers epigenetic regulation drug molecule design, target selection, and precise modulation.

YolTech Therapeutics Secures Approximately $45 Million in Series B Financing Led by AstraZeneca and CICC CapitalThe company owns a fully integrated technology platform, including proprietary CRISPR nucleases, base editors, and lipid nanoparticle delivery systems, enabling precise, efficient, and tissue-specific gene editing. Currently, the company has advanced four clinical-stage projects targeting transthyretin amyloidosis (ATTR), familial hypercholesterolemia (HeFH), primary hyperoxaluria type 1 (PH1), and β-thalassemia/sickle cell disease (TDT/SCD).

Stellar Eyes Biotech Completes Tens of Millions of Yuan in Series A2 Financing, Focusing on the Development of Ophthalmic Gene Therapy DrugsThe focus will be on supporting the Phase 2 clinical trial of the core product XMVA09 for the treatment of wet age-related macular degeneration (AMD), while simultaneously advancing the pipelines for dry AMD and thyroid eye disease. The company possesses two key core technologies: the AAV-antibody gene drug platform (bispecific antibody optimization + capsid screening) and the gene editing platform.

In addition to gene editing, other cutting-edge technology platforms and novel therapies have also gained capital favor. In the United StatesDewpoint Therapeutics Dedicated to developing the world's first biomolecular condensate modulator (c-mod), its project targeting gastric cancer is about to enter clinical trials. JapanMetagen Therapeutics(B Series 23.2 million yen) and the United KingdomBoobyBiome(Seed Round 2.5 Million Pounds) Focused on Microbiome Therapy Development. In ChinaLB Pharma(A++ Round) Focus on drug development for bone and joint diseases. See the table below for details.

Readers, please star ⭐Chuangjianhui to receive updates第一时间.

Disclaimer: This article is for information exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: Welcome to share to Moments. Unauthorized media or institutions are prohibited from reprinting or copying in any form to other platforms. For reprint authorization, please contact"Innovation Insight"Contact us through the WeChat Official Account.

More Data Content Recommendations

Click "InSee", Sharing Chuangjian Hui Health New Trends